{"id":"W2503710795","doi":"10.1200/jco.2016.34.15_suppl.3553","title":"Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: Results of the GERCOR DREAM phase III trial.","year":2016,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hôpital Charles-Le Moyne","funders":"","keywords":"Medicine; Bevacizumab; Hazard ratio; Internal medicine; Quality of life (healthcare); Clinical endpoint; Maintenance therapy; Tolerability; Randomization; Proportional hazards model; Oncology; Randomized controlled trial; Visual analogue scale; Colorectal cancer; Confidence interval; Surgery; Cancer; Adverse effect; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002965743,0.0009135033,0.002054095,0.0002219285,0.0001835972,0.0008924872,0.0006516998,0.0008101669,0.002456144],"category_scores_gemma":[0.001857735,0.0003103509,0.002364505,0.0003167629,0.0004905015,0.0005751046,0.0004680839,0.002056333,0.0004406272],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008021111,"about_ca_system_score_gemma":0.0008873026,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009148895,"about_ca_topic_score_gemma":0.002405241,"domain_scores_codex":[0.9992424,0.0004546534,0.00004475891,0.0001018189,0.00007005302,0.00008632403],"domain_scores_gemma":[0.99925,0.0001984497,0.0002118654,0.00007819846,0.00005173777,0.0002097091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.910272,0.005717592,0.008523908,0.001476364,0.004294519,0.00007356387,0.00008811457,0.001186662,0.003312729,0.0001685457,0.004239502,0.06064663],"study_design_scores_gemma":[0.817263,0.1356089,0.0351944,0.0002225654,0.004562741,0.0002394119,0.00008092265,0.001760633,0.0007734388,0.000447485,0.003799027,0.00004746466],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.97702,0.01724862,0.0003166414,0.0009144148,0.000313412,0.0006401574,0.001874508,0.00005205483,0.001620085],"genre_scores_gemma":[0.9845186,0.004609758,0.001254337,0.00131129,0.0003370052,0.001141031,0.004725202,0.00002081015,0.002081869],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002965743,"threshold_uncertainty_score":0.01568455,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1695286658192528,"score_gpt":0.4872432541027403,"score_spread":0.3177145882834875,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}